The innovative mechanism of action employed in GenSpera's lead investigational agent, mipsagargin, is unique in the way it is thought to destroy tumors and offers another option in how we target cancer.

Mipsagargin consists of a thapsigargin derivative, 12ADT, coupled to a peptide that helps solubilize the prodrug and prevents its internalization into cells until it is removed.

The mechanism of action works by targeting the enzyme prostate-specific membrane antigen (PSMA), which is highly expressed on the surface of all cancer tumor vasculature and in prostate cancer cells. PSMA recognizes and dissolves the peptide, releasing the active ingredient 12ADT which then enters the cell bringing about cell death.